Meet the teams: Venture Challenge Fall 2022
Last week five teams started their Venture Challenge adventure with the first 3-day bootcamp. Already in these three days the teams made huge progress. Amongst many other things, they built an initial Value Proposition that they will be validating in the coming weeks.
Lisanne Blauw from Thuja Capital shared investor insights with the teams. Tess Korthout and Niels Wheeler from Johnson & Johnson explained why and how to interact with Big Pharma.
Thanks to Pivot Park for your support and hosting us at your campus.
In the coming weeks the Venture Challenge participants will go out and validate their value proposition with customers and key opinion leaders before returning for a second three-day workshop beginning of November.
Meet our teams:
NatInLab: Developing the next generation of protease inhibitor therapeutics.
From left to right
Jakub Tomczak
Ewelina Weglarz-Tomczak
Devon Visser
PrecorDx develops a novel, non-invasive diagnostic platform, initially aimed to reduce hospitalization and mortality in heart failure patients.
From left to right
Bart Steensma
Nico van den Berg
Jaap de Bruin
D4 Diagnostics: A digital revolution in immune cell quantification
From left to right
Jasper Keijman
Nelleke Gruis
Pieter van der Velden
Beephonix: Nature inspired superior hearing for all people
From left to right
Klaas-Jan Kakebeeke
Martijn Agterberg
Marc van Dorth
MoVax Biopharma: Changing the world of vaccination
From left to right
Wim van der Wilden
Carla van Heck
Christian Südfeld
